Medicamen Biotech Ltd
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]
- Market Cap ₹ 522 Cr.
- Current Price ₹ 411
- High / Low ₹ 765 / 355
- Stock P/E 46.9
- Book Value ₹ 165
- Dividend Yield 0.24 %
- ROCE 9.28 %
- ROE 6.60 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 152 to 102 days.
Cons
- Company has a low return on equity of 8.41% over last 3 years.
- Dividend payout has been low at 8.73% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
64 | 73 | 78 | 67 | 82 | 112 | 123 | 117 | 110 | 115 | 138 | 172 | 173 | |
64 | 68 | 73 | 62 | 71 | 95 | 105 | 99 | 90 | 91 | 113 | 146 | 150 | |
Operating Profit | -0 | 5 | 5 | 6 | 12 | 17 | 17 | 18 | 20 | 24 | 25 | 26 | 23 |
OPM % | -0% | 7% | 6% | 8% | 14% | 15% | 14% | 15% | 18% | 21% | 18% | 15% | 14% |
1 | 1 | 1 | 1 | 0 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | 2 | |
Interest | 4 | 4 | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 4 | 4 |
Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 7 | 7 |
Profit before tax | -5 | 0 | 0 | 1 | 6 | 14 | 18 | 17 | 17 | 18 | 17 | 17 | 15 |
Tax % | 1% | 44% | -267% | 32% | 19% | 27% | 31% | 26% | 25% | 18% | 13% | 21% | |
-5 | 0 | 0 | 0 | 5 | 10 | 12 | 12 | 12 | 15 | 15 | 13 | 11 | |
EPS in Rs | -5.81 | 0.10 | 0.46 | 0.48 | 4.91 | 8.89 | 10.28 | 10.04 | 10.22 | 12.20 | 11.86 | 10.46 | 8.79 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 12% | 10% | 5% | 10% | 8% | 8% | 10% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 7% |
3 Years: | 16% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | 65% |
5 Years: | 2% |
3 Years: | 2% |
TTM: | -30% |
Stock Price CAGR | |
---|---|
10 Years: | 43% |
5 Years: | 4% |
3 Years: | -14% |
1 Year: | -44% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 9% |
3 Years: | 8% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 9 | 10 | 10 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 |
Reserves | 7 | 7 | 7 | 8 | 15 | 63 | 75 | 110 | 122 | 136 | 181 | 196 |
17 | 15 | 21 | 19 | 18 | 14 | 12 | 11 | 19 | 26 | 26 | 30 | |
33 | 33 | 31 | 23 | 30 | 28 | 38 | 43 | 39 | 52 | 57 | 55 | |
Total Liabilities | 65 | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 294 |
23 | 22 | 20 | 19 | 19 | 25 | 24 | 34 | 90 | 92 | 92 | 91 | |
CWIP | 0 | 1 | 0 | 0 | 0 | 0 | 15 | 40 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 8 |
42 | 42 | 49 | 41 | 54 | 92 | 97 | 100 | 101 | 131 | 180 | 195 | |
Total Assets | 65 | 65 | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 294 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-2 | 5 | -3 | 6 | 4 | -5 | 4 | 12 | 13 | 5 | -4 | -0 | |
-1 | -1 | 0 | -1 | -2 | -8 | -15 | -39 | -18 | -8 | -8 | -9 | |
2 | -4 | 3 | -5 | -1 | 33 | -4 | 21 | 6 | 4 | 28 | 3 | |
Net Cash Flow | -1 | 1 | -0 | 0 | 0 | 20 | -14 | -6 | 1 | 1 | 17 | -6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 105 | 102 | 124 | 87 | 114 | 126 | 129 | 137 | 165 | 193 | 159 | 102 |
Inventory Days | 122 | 95 | 95 | 95 | 102 | 77 | 67 | 85 | 28 | 188 | 230 | 237 |
Days Payable | 225 | 209 | 187 | 160 | 165 | 118 | 134 | 160 | 161 | 291 | 232 | 152 |
Cash Conversion Cycle | 1 | -13 | 32 | 22 | 51 | 85 | 62 | 62 | 32 | 91 | 157 | 188 |
Working Capital Days | 50 | 44 | 80 | 83 | 96 | 135 | 151 | 162 | 166 | 207 | 213 | 178 |
ROCE % | -3% | 13% | 12% | 12% | 25% | 25% | 20% | 15% | 13% | 12% | 11% | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Aug - Newspaper Publication for the Quarterly Results ended on 30.06.2024 publish at Financial Express and Jansatta
- Business Responsibility and Sustainability Reporting (BRSR) 13 Aug
- Board Meeting Outcome for Outcome Of Board Meeting 13 Aug
- Financial Results For The Quarter Ended On 30.06.2024 13 Aug
- Board Meeting Intimation for The Approval Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On June 30, 2024 And For Approval Of Draft Financial Results For The FY 2023-24 7 Aug
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2][3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.